This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, Y. Articles by Rodriguez, R. Search for Related Content PubMed PubMed Citation Articles by Li, Y. Articles by Rodriguez, R.

Prostate-specific Expression of the Diphtheria Toxin A Chain (DT-A)

Studies of Inducibility and Specificity of Expression of Prostate-specific Antigen Promoter-driven DT-A Adenoviral-mediated Gene Transfer¹

Brady Urological Institute, Johns Hopkins Hospital [Y. L., J. M., F. F., R. R.], and Johns Hopkins Oncology Center, Department of Medical Oncology [M. K., M. C., J. S.], Baltimore, Maryland 21287-2101

Diphtheria toxin (DT) is a potent inhibitor of protein synthesis. As little asa single molecule of DT can result in cell-cycle independent cell death. This profound potency has led to difficulties in the development of DT as a suicide gene in cancer gene therapy, because toxicity appears to be related primarily to the fidelity of basal gene expression and the yield of viral titer. We evaluated the feasibility of prostate-specific DT gene therapy by cloning the catalytic domain (A chain) of DT under the control of the prostate-specific antigen (PSA) promoter, the PSA promoter and enhancer, or the cytomegalovirus promoter. The data on expression of DT from the plasmid constructs demonstrate that the basal level of DT gene expression determines the toxicity. To better test the potential therapeutic efficacy of DT suicide gene therapy, we first developed a DT-resistant adenoviral packaging line (293DTR). This allowed us to manufacture a relatively high titer adenoviral vector encoding the DT-A gene under the control of the PSA promoter and enhancer (Ad5PSE-DT-A) as well as an attenuated DT-A virus (Ad5PSE-tox176). In vitro studies showed that our viral constructs preferentially kill PSA-positive prostate cancer cells in the presence of exogenous androgen (R1881). In vivo studies showed that the nu/nu mice with PSA-positive cancer cell LNCaP xenograft treated with wild-type DT-A virus had a rapid regression of tumors and survived over a year without tumor progression, whereas the attenuated DT-A virus restricted tumor growth for only 1 month. The same constructs had no significant effect on the non-PSA-secreting cell line DU-145. These encouraging results suggest that DT-A viral gene transfer may ultimately have a therapeutic role in the treatment of advanced human prostate cancer.

This article has been cited by other articles:

				C.-Y. Wang, F. Li, Y. Yang, H.-Y. Guo, C.-X. Wu, and S. Wang Recombinant Baculovirus Containing the Diphtheria Toxin A Gene for Malignant Glioma Therapy Cancer Res., June 1, 2006; 66(11): 5798 - 5806. [Abstract] [Full Text] [PDF]

				W. S. Yang, S.-O Park, A-R. Yoon, J. Y. Yoo, M. K. Kim, C.-O. Yun, and C.-W. Kim Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Mol. Cancer Ther., June 1, 2006; 5(6): 1610 - 1619. [Abstract] [Full Text] [PDF]

				N. Koshikawa and K. Takenaga Hypoxia-Regulated Expression of Attenuated Diphtheria Toxin A Fused with Hypoxia-Inducible Factor-1{alpha} Oxygen-Dependent Degradation Domain Preferentially Induces Apoptosis of Hypoxic Cells in Solid Tumor Cancer Res., December 15, 2005; 65(24): 11622 - 11630. [Abstract] [Full Text] [PDF]

				E. Mitrofanova, R. Unfer, N. Vahanian, W. Daniels, E. Roberson, T. Seregina, P. Seth, and C. Link Jr. Rat Sodium Iodide Symporter for Radioiodide Therapy of Cancer Clin. Cancer Res., October 15, 2004; 10(20): 6969 - 6976. [Abstract] [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]